We propose to construct and validate an early HCC risk prediction model in a multicenter retrospective cohort of hepatitis B-related fibrosis/cirrhosis patients, using multimodal data encompassing longitudinal clinical data, serum glycomics profiles, and liver biopsy histopathological images.
Aged ≥18 years, both sexes eligible.
Diagnosed with hepatitis B-related liver fibrosis or cirrhosis based on clinical assessment or liver histopathology.
Undergoing antiviral treatment.
Follow-up duration between 0.5- 5 years.
Diagnosis of Hepatocellular carcinoma (HCC) or liver transplantation at baseline or within 6 months after baseline/enrollment.
Coexisting other chronic liver diseases, such as genetic/metabolic liver diseases, drug-induced liver injury, or severe steatotic liver disease.
Coexisting other malignancies (except those considered cured).
Beijing Friendship Hospital
Lead sponsor
Guangzhou Eight People's Hospital, Guangzhou Medical University
Collaborator
The NO.2 People's Hospital of Lanzhou
Collaborator
Yuncheng People's Hospital
Collaborator